Robert Zeldin
Chief Tech/Sci/R&D Officer at MEIRAGTX HOLDINGS PLC
Net worth: 553 597 $ as of 2024-02-28
Profile
Robert K.
Zeldin occupies the position of Chief Medical Officer for MeiraGTx Holdings Plc.
He previously was Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc., Senior Vice President-Global Clinical Development at Stallergenes SA, Chief Medical Officer at Ablynx NV, Medical Officer at Center for Biologics Evaluation & Research, Chief Medical Officer of Immunovant, Inc. and Vice President at Novartis Pharmaceuticals Corp.
He received a doctorate from Tufts University School of Medicine and an undergraduate degree from The Johns Hopkins University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
MEIRAGTX HOLDINGS PLC
0.14% | 2024-01-16 | 89,724 ( 0.14% ) | 553 597 $ | 2024-02-28 |
Robert Zeldin active positions
Companies | Position | Start |
---|---|---|
MEIRAGTX HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 2020-08-04 |
Former positions of Robert Zeldin
Companies | Position | End |
---|---|---|
ACCELERON PHARMA INC. | Chief Tech/Sci/R&D Officer | 2019-04-04 |
STALLERGENES | Chief Tech/Sci/R&D Officer | 2014-12-31 |
IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | - |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Chief Tech/Sci/R&D Officer | - |
Training of Robert Zeldin
The Johns Hopkins University | Undergraduate Degree |
Tufts University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
IMMUNOVANT, INC. | Health Technology |
Private companies | 6 |
---|---|
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Stallergenes SA
Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Commercial Services |
MeiraGTx Holdings Plc |